COMPARISON OF LANTUS AND NPH INSULIN IN THE DAWN PHENOMENON

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 对于1型糖尿病，挑战一直是将血糖保持在尽可能接近非糖尿病范围。使用具有不同活性的胰岛素和持续皮下注射胰岛素的胰岛素方案在模拟正常胰腺功能方面取得了一定的成功。提供更稳定的基础生理胰岛素水平的胰岛素类似物导致了新的每日多次注射方案的发展。我们将研究超长效甘精胰岛素和NPH对1型糖尿病患者早期AM(黎明现象)血糖控制的不同影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. In type 1 diabetes, the challenge has been to maintain blood glucose as close to the non-diabetic range as possible. Insulin regimens using insulins with varied activity profiles and continuous subcutaneous insulin infusion have been somewhat successful in mimicking normal pancreatic function. Insulin analogues that provide more stable, basal physiologic insulin levels have led to the development of newer multiple daily injection regimens. We will investigate the differential effects of the very long-acting insulin glargine vs NPH on glycemic control during the early AM (dawn phenomenon) in individuals with type 1 diabetes.